Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
出版年份 2016 全文链接
标题
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
作者
关键词
JAK inhibition, Myelofibrosis, Myeloproliferative neoplasm, Polycythemia vera, Ruxolitinib
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 6, Pages 1125-1142
出版商
Springer Nature
发表日期
2016-03-26
DOI
10.1007/s00280-016-3012-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis
- (2015) Christophe Desterke et al. MEDIATORS OF INFLAMMATION
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
- (2014) Matteo Molica et al. ANNALS OF HEMATOLOGY
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Therapy for myeloproliferative neoplasms: when, which agent, and how?
- (2014) H. L. Geyer et al. BLOOD
- Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
- (2014) H. L. Geyer et al. BLOOD
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Comorbidities predict worse prognosis in patients with primary myelofibrosis
- (2014) Kate J. Newberry et al. CANCER
- Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples
- (2014) Masataka Hosoi et al. EXPERIMENTAL HEMATOLOGY
- Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
- (2014) F. Lussana et al. HAEMATOLOGICA
- Outcomes following splenectomy in patients with myeloid neoplasms
- (2014) Kristy L. Rialon et al. JOURNAL OF SURGICAL ONCOLOGY
- Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
- (2014) Lana X. Tong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
- (2014) T Stübig et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia
- (2014) Naval Daver et al. LEUKEMIA RESEARCH
- Are we altering the natural history of primary myelofibrosis?
- (2014) Michael R. Savona LEUKEMIA RESEARCH
- Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis
- (2014) Danijela Lekovic et al. MEDICAL ONCOLOGY
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm
- (2013) Raajit Rampal et al. CURRENT OPINION IN HEMATOLOGY
- The role of cytokines in the initiation and progression of myelofibrosis
- (2013) Hans C. Hasselbalch CYTOKINE & GROWTH FACTOR REVIEWS
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- JAK inhibitors: beyond spleen and symptoms?
- (2013) F. Cervantes et al. HAEMATOLOGICA
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
- (2013) R. A. Mesa et al. HAEMATOLOGICA
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
- (2013) Ruben A Mesa et al. Journal of Hematology & Oncology
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
- (2013) Naval Daver et al. LEUKEMIA RESEARCH
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis
- (2013) Sonja Burgstaller et al. WIENER KLINISCHE WOCHENSCHRIFT
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
- (2013) Srdan Verstovsek et al. OncoTargets and Therapy
- Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
- (2012) O. Benjamini et al. BLOOD
- Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
- (2012) T. Barbui et al. BLOOD
- Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
- (2012) V. Gupta et al. BLOOD
- Risk models predicting survival after reduced-intensity transplantation for myelofibrosis
- (2012) Haefaa Alchalby et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
- (2012) Kenneth C.H. Fearon et al. Cell Metabolism
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
- (2012) Umberto Gianelli et al. MODERN PATHOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcome of pomalidomide therapy in myelofibrosis
- (2011) Kebede H. Begna et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
- (2011) E. Jabbour et al. BLOOD
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
- The 2008 World Health Organization classification system for myeloproliferative neoplasms
- (2009) Ayalew Tefferi et al. CANCER
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
- (2008) Omar I. Abdel-Wahab et al. Annual Review of Medicine
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now